| abstract |
The invention relates to novel 3-aryl or 3-heteroaryl-1,2,4-oxadiazoles which are in particular cannabinoid receptor ligands and can be used as diagnostic and therapeutic agents, in particular in neurological, neurodegenerative and psychiatric disorders, as well as a Process for their preparation. The ligands are particularly suitable as radiodiagnostic agents for detecting cannabinoid receptor by means of positron emission tomography (PET). Preferred 3-aryl- or 3-heteroaryl-1,2,4-oxadiazoles according to the invention are distinguished by a high affinity and selectivity for the human CB 2 receptor. The process according to the invention is distinguished by a nucleophilic aromatic substitution of an aromatic or heteroaromatic radical in the 3-position of a 1,2,4-oxadiazole ring which has not hitherto been described in the prior art. |